Immunome reported a decisive Phase III result showing its oral gamma secretase inhibitor dramatically reduced disease worsening in progressing desmoid tumors. The trial met its primary endpoint with an 84% reduction in risk of progression or death versus placebo, prompting Immunome to plan an NDA submission to the U.S. FDA in the coming quarter. The data mark a rare, large-effect outcome in a small‑population oncology indication.